UWA, COVS and LEI COVS is effectively the academic arm of LEI through which competitive research grants are managed and to which academic appointments.

Slides:



Advertisements
Similar presentations
Research Leaders: Meeting the challenge Mark Walport 19 November 2008.
Advertisements

Personalized Medicine in California Kathryn Lowell, Deputy Secretary for Life Sciences and Health Systems February, 2009.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
The Lung Institute of Western Australia &CAARR Postgraduate Research For the six million Australians who struggle to take a breath, LIWA offers support.
Orientation Information Session Dr Shaun Roman B.Biotechnology.
OUT OF SIGHT The Rise and Rise of Diabetes and the Need for a Nationwide Retinopathy Screening Program Dr Mohamed Dirani Health Services and Evaluative.
Research Activities at the Dean McGee Eye Institute Gregory Skuta, MD Professor and Chairman, Department of Ophthalmology President and CEO, Dean McGee.
Keratoconus Research Innovation at CERA Dr Srujana Sahebjada Research Fellow, Optometrist Ocular Genetics Unit.
Department of Medicine Task Force on Research. Committee Charge  Develop a unifying vision to become leaders in translational research Achieve top 10.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
UCL Institute of Ophthalmology Department of Genetics
Hepatitis B.
ANIMAL MODELS HIV Cure Research Training Curriculum The HIV CURE training curriculum is a collaborative project aimed at making HIV cure research science.
Combating major diseases Gender aspects in research Gender aspects in research have a particular relevance to this theme as risk factors, biological mechanisms,
Influencing Change in Research, Treatment Protocols, and New Drug Development.
Macular Degeneration Amanda Thompson Mrs. Jensen Block 3.
Who am I? A Brief Bio PhD with John Schrader at The Biomedical Research Centre (UBC) Undergrad at Simon Fraser University Genetics: 3 summers in a Drosophila.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Diabetes Eye Screening in Minority Populations Owsley C, McGwin G Jr, Lee DJ,
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Laser Intervention in Early Age Related Macular Degeneration
1 Course. 3 U nique options. Biomedical Science Discoveries, Diagnostics and Cures 1.
Age-Related Macular Degeneration Treatment Robert Thottam.
Michael Peterson March 21, Maximize the gift of donation Develop novel surgical treatments Improve corneal transplantation Cure disease.
Introduction to stem cells Stem cell Community Forum Raymond Wong, PhD Neuroregeneration Research Unit, CERA.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Greenview Hepatitis C Fund Deborah Green Home: Cell: /31/2008.
Supporting research and patient outreach for FacioScapuloHumeral Muscular Dystrophy (FSHD), one of the most common forms of muscular dystrophy. Progress.
OLIVER BIRD COLLABORATIVE CENTRE NEWCASTLE UNIVERSITY Oliver Bird Collaborative Centre in Newcastle In 2003 we were one of five Centres awarded a grant.
121 Intramural Biomedical Projects in Rare Diseases (PIBER) Support Platforms for Research into Rare Diseases (PITER) Management Office Scientific Director.
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
Infections of the GI Tract November 19, 2007 NCDD Meeting Chair: Mitchell B. Cohen, MD Vice Chair: Richard S. Blumberg, MD.
Personalised Eye Consultation (PEC) to improve outcomes in DR Dr Eva Fenwick (Research Fellow) Behavioural Research in Ophthalmology Prue Spencer, Project.
Health environment. Is a health background necessary?
Faculty of Medical Sciences School of Biomedical Sciences Dr Edwin Williams Director of Studies
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
Recognition Of Team Science Faculty Appointments, Promotions and Titles at The Geisel School of Medicine at Dartmouth “Recognition by peers as an investigator.
MRC Mouse Network Jan 2012 Mouse eyes and vision research consortium Prof Marcela Votruba PhD FRCOphth Prof Ian Jackson PhD.
Studies of HIV Eradication: a Case for Using NHP Models Guido Silvestri, MD Yerkes National Primate Research Center Emory University School of Medicine.
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
Luu CD, Dimitrov PN, Robman L, et al. Role of flicker perimetry in predicting onset of late-stage age-related macular degeneration. Arch Ophthalmol. 2012;130(6):
NEI ARRA implementation As of March 30, Administrative Supplements The NEI is participating in two programs offering administrative supplements.
Visual Impairment. Factors Affecting Visual Function and Their Treatment Visual Acuity - ability to see "detail" –Measured using testing distance/letter.
Parstatin: a novel pharmacological target for the development of new agents in the treatment of cardiovascular diseases Nikos E. Tsopanoglou Assistant.
Genetic Repositories Australia BACKGROUND GRA supported by an NHMRC Enabling Facility Grant awarded in  GRA supported by an NHMRC Enabling Facility.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Consortium for Interdisciplinary Studies on Science for Aging.
DIABETES Naturopathic Doctors Ontario. Insulin Resistance Insulin Insufficiency Pancreatic cell damage (auto-immune, viral infection) High Blood Sugar.
Nina Holst, Betanien Hospital, Skien. Bergen 15. June 2015
Blindness or low vision effects more than 3 million Americans 40 years and older, and this number is projected to reach 5.5 million by In addition.
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
Chronic Visual Loss. CHRONIC VISUAL LOSS 1. Measure intraocular pressure with a tonometer 2. Evaluate the nerve head 3. Evaluate the clarity of the lens.
The latest from the Australian Study of Keratoconus Dr Srujana Sahebjada Postdoctoral Research Fellow/Optometrist Ocular Genetics Unit.
Clinical Science in Yorkshire and Humber Alexis Moore Lead Clinical Scientist for Training (Physical Leeds Teaching Hospitals NHS Trust.
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
Functional Vision Endpoints: OCTGT Perspective Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation and.
Recent Studies Funded by the Progressive MS Alliance Tim Coetzee, PhD ACTRIMS 2016.
Macular Degeneration Chaminda Unantenne RN,MS,MSN  
How Diabetes Steals Vision from Your Patients
Passion is our driver, strategy is our compass May 6, 2016.
SuPAR and sICAM-1 as Immune Markers for Treatment Response in Ethiopian TB patients with and without HIV co-infection Wegene T. Mekasha ICASA, Addis Ababa.
Saving vision using stem cells and "Cut and Paste" technology
Understanding the role of your immune system:
TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE
Using stem cells to understand blinding eye diseases
James M. Fadool Biological Science
Biomedical Therapies Foundation Standard 1: Academic Foundation
From Bench to Clinical Applications: Money Talks
Presentation transcript:

UWA, COVS and LEI COVS is effectively the academic arm of LEI through which competitive research grants are managed and to which academic appointments are made LEI provides extensive office and laboratory research facilities, equipment and infrastructure for research groups LEI/COVS provide unique translational opportunities. Institute bridges clinical, teaching and research work

Molecular Ophthalmology Development and characterization of animal models for age- related macular degeneration and ocular neovascularisation The potential of marrow stromal cells for cell-based therapeutic treatment of ocular diseases Establishment of a DNA Bank for retinitis pigmentosa sufferers in WA and their families Antisense therapy for ocular diseases Gene-based treatment strategies for diabetic retinopathy Computational technology to model biological processes Preclinical evaluation of sFlt secretion gene therapy for retinal and choroidal neovascularisation

rAAV.sFlt-1 secretion gene limits vascular leakage Shen et al., Archives of Ophthalmol 122: (2004) macula 3 months 24 months 12 months rAAV.GFP rAAV.sFlt-1 Publications ( ): 76

Funding NHMRC Foundation for Fighting Blindness USA Juvenile Diabetes Research Foundation Lions Save Sight Foundation Retina Australia NHMRC “Ten of the best” award in 2004

Physiology and Pharmacology Advanced New Therapeutics and Diagnostics in Retinal Diseases and Glaucoma Microelectrode measurements of retinal oxygen distribution Animal models of retinal disease and glaucoma Retinal blood flow and vascular disease New therapeutic strategies Basic research and clinical projects 6 PhDs, 4 MDs, 3 Support Staff plus students

Achievements novel laser technologies dissolving tube for the treatment of glaucoma > 200 research papers and 10 patents consecutive NHMRC Program Grants ARC Centre of Excellence in Vision Science >$14 Million in NHMRC and ARC funding major commercialisation of new glaucoma treatment

Genetics and Population Health Glaucoma Inheritance Study in Tasmania (GIST) one of the largest glaucoma biobanks >5,000 DNA samples & clinical data >50 papers, including Science, Nature Genetics, New England Journal Med discovery of the myocilin and Caveolin genes. Western Australian Glaucoma Inheritance Study established in WA Twins Eye Study in Tasmania and Brisbane genome wide analysis to identify genes associated with ocular measures related to disease Norfolk Island Eye Study (NIES) study cause of eye diseases incl glaucoma, myopia and AMD Strabismus pedigrees of strabismus patients in Tasmania and now Western Australia

Raine Eye Health Study ophthalmic examinations on 2,167 prospectively followed Raine Birth Cohort members (now 20 yrs, have 610,000 GWAS analysis) establish an ophthalmic baseline for a cohort that can be followed through later adult life Busselton Healthy Ageing Study longitudinal cohort study of 5,000 adults collect epidemiological, clinical and genetic data on a range of conditions of economic and public health importance in an ageing population

Immunology and Virology International leaders in immunology and viral immunogenetics model of persistent viral infections Seminal research in innate immunity multiple papers in high impact journals (Science, Nature Immunology x4, Immunity, J Exp Medicine). Many >200/paper citations Identified immune responses required to limit persistent viral infections Clinical relevance – CMV, HEP B, HIV, transplantation Continuous NHMRC funding since 1999, NHMRC Program Grant in 2010

Ocular Immunology – new initiative commenced in 2008 Immune responses to ocular viral infection What tissues/cells are infected Impact of the virus Impact of anti-viral immune responses Immune responses to ocular gene therapy First study of immune responses to gene therapy in small and large animal models Preclinical data required for TGA approval of gene therapy Impact of systemic infection on inflammation in the eye First evidence of impact of systemic disease on CNS Identified relevant mechanisms Important clinical connotations

New models of autoimmune disease of the eye Autoimmune uveitis First model of spontaneous autoimmune disease of the eye How is tolerance maintained Can study disease progression and impact of intervention Autoimmune disease with ocular complications – AS associated uveitis First mouse model of SpA Identify cause including microbial trigger Define relevant mechanisms Can trial intervention strategies in vivo Several publications including in the pipeline (in preparation and/or submitted)

New research ventures Stem Cell Research Indigenous Health